News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Amol Akhade: Use of Dostarlimab plus niraparib in first line Advanced Ovarian Cancer
Amol Akhade/LinkedIn
Dec 25, 2024, 03:35

Amol Akhade: Use of Dostarlimab plus niraparib in first line Advanced Ovarian Cancer

Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared a post on LinkedIn:

“ENGOT- OV44 / First Trial .

 Use of Dostarlimab plus niraparib plus chemotherapy in first line Advanced Ovarian cancer has improved PFS .

 Trial is Negative for OS ( headline does not say so )

 It has complicated design.

 It will be intresting to see the detail data once presented.”

Amol Akhade: Use of Dostarlimab plus niraparib in first line Advanced Ovarian Cancer

Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. 

Amol Akhade cancer chemotherapy Dostarlimab fight against cancer Global fight against cancer Niraparib OncoDaily Oncology Ovarian Cancer Reliance Hospitals Suyog Cancer Clinics
Special Coverage
Blog
Apr 13, 2025, 19:03
Tigran Byuzandyan: Delegation from the National Oncology Center of Armenia Explores Collaboration with Heidelberg University Hospital
Blog
Apr 13, 2025, 18:24
Akhil Santhosh: First-Line Adagrasib and Pembrolizumab for Metastatic NSCLC
Blog
Apr 13, 2025, 18:15
12th Annual Cholangiocarcinoma Foundation Conference Comes to a Close
Blog
Apr 13, 2025, 17:50
Noemi Reguart: First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy in SCLC
Blog
Apr 13, 2025, 17:15
Applications are open for the M2ICOS project - European School of Oncology
Stories
Apr 13, 2025, 17:11
From Resident to Survivor: Dr. Jessica Firdman Moore’s cancer journey at Sylvester Comprehensive Cancer Center
Blog
Apr 13, 2025, 17:05
Aruni Ghose: OncoFlow to evaluate AI models across the cancer continuum for clinical adoption
Blog
Apr 13, 2025, 16:53
Heitham Hassoun: All great hospitals are so much more than places to heal
Blog
Apr 13, 2025, 16:28
Rasha Aboelhassan: A fruitful International Society of Clinical Oncology meeting on breast cancer
Blog
Apr 13, 2025, 16:17
The Bulgarian government has adopted an expanded national vaccination programme for HPV - European Cancer Organisation
Blog
Apr 13, 2025, 16:17
Chinmay Jani: SCLC no longer left behind
Blog
Apr 13, 2025, 16:12
Dr. Ira Mellman Joins the Parker Institute as President of Research